Grade 2 gliomas are malignant brain tumours affecting otherwise healthy adults. Although the long-term prognosis is poor, many patients are well and may have a high quality of life for several years. There is, however, a large variability in the natural course of the disease which makes it essential to identify patients who might benefit from early surgery or radio-therapy. The aim of the present thesis was to define new and clinically useful prognostic markers that may assist in the initial treatment decision and in patient follow-up. A retrospective study of 189 patients with gliomas WHO grade 2 showed no advantage in survival of early tumour resection or radiotherapy, and confirmed that histological subtype and patient age are the most important predictors of survival (I). In 89 patients, the pre-treatment uptake of 11C-methionine (MET) measured with positron emission tomography (PET) was identified as a prognostic marker for survival (II). At the time of tumour progression, irradiated tumours demonstrated signs of a residual radiotherapeutic effect that correlated with the pre-treatment uptake of MET (III). Pre-treatment uptake of MET may, therefore, be important both in predicting the natural course of the disease and the response after treatment. Immunohistochemical staining of 40 tumour samples showed an inverse association between the number of tumour cells expressing platelet-derived growth factor alpha receptor (PDGFRa) and survival (IV). Also, a reduction was observed in the number of receptor-positive cells after malignant transformation, supporting the prognostic value of PDGFRa. Lumbar puncture was performed in eight patients with newly diagnosed low-grade gliomas to identify three important growth factors in tumour development. Neither PDGF nor vascular endothelial growth factor (VEGF) were detected in the cerebrospinal fluid (CSF), and fibroblast growth factor 2 (FGF-2) was measurable at extremely low concentrations in two of the patients (V). A proteome screening of the CSF, using two-dimensional gel electrophoresis and mass spectrometry, detected alpha 2-HS glycoprotein at significantly higher concentrations than in a control group (VI). This glycoprotein emerges as a novel substance in glioma research and may be of great interest because of its suggested involvement in the embryonic development of the neocortex.

Understanding the differential bonding mechanics underlying bleeding disorders is of crucial importance to human health. In this research insight is provided into how four of these bleeding disorders (each with somewhat similar clinical characteristics), work at the molecular bond level. The bleeding diseases studied here can result from defects in the platelet glycoprotein (GP) Ibα the von Willebrand factor (vWF) molecule, or the ADAMTS-13 enzyme. Types 2B and 2M von Willebrand Disease (VWD) result in excess bleeding, yet type 2B has increased binding affinity between platelet GPIbα and vWF, while type 2M has decreased binding affinity between these two molecules. Platelet type VWD (pt-VWD) causes mutations in the GPIbα molecule and has similar characteristics to type 2B VWD. Further, in thrombotic thrombocytopenic purpura, bleeding results when there is a lack of active ADAMTS-13 enzyme. Each disease results in patient bleeding, but due to different mechanisms. This dissertation will explore the bonding mechanics between GPIbα and vWF and how they are altered in each disease state. To observe the GPIbα-vWF bonding mechanics, rolling velocities, transient tethering lifetimes, and tether frequency were determined using a parallel plate flow chamber. Data from these experiments suggest that wt-wt interactions are force dependent and have biphasic catch-slip bonding behavior. The data show that the shear stress at which the maximum mean stop time occurs differs between gain-of-function and loss-of-function mutations. Using similar methods, we study the changes resulting from pt-VWD mutations in GPIbα, and find that the catch bond seen for wt-wt interactions is lost for these mutations. Further, the data suggest that interactions with gain-of-function GPIbα mutations may be transport rather than force dependent. Finally, how the GPIbα-vWF tether bond changes for thrombotic thrombocytopenic purpura was also investigated to show that the bond lifetime in the absence of the enzyme is increased presenting a possible rationale for why bleeding occurs in this disease. Overall, the data show how the bonding mechanics of the GPIbα-vWF tether bond differ in four bleeding diseases. Further, these observations offer potential explanations for how these changes in the bonding mechanism may play a role in the observed patient bleeding.

Purpose: To determine whether reduced serum levels of AHSG and elevated levels of BMP-2, 4, 7 are associated with post-arthroplasty HO. Patients: Thirty arthroplasty patients were included, 15 with evidence of peri-articular HO and 15 without (NHO). Methods: Blood samples were collected from all patients ≥ 8 weeks after arthroplasty. Analytes were measured using ELISAs. Mann-Whitney U tests were performed to compare serum analyte concentrations between HO and NHO groups, and between arthroplasty patients and healthy humans. Results: There is no difference in serum concentrations of AHSG, BMP-2, 4, 7 between HO and NHO patients. Arthroplasty patients showed significantly higher BMP-2 and BMP-4 and lower AHSG serum levels compared to healthy humans (p < 0.01). Conclusion: Baseline BMP-2, 4, 7 and AHSG serum levels are not markers of acquired HO. However, elevated baseline levels of BMP- 2, 4 and reduced levels of AHSG appear to be markers of severe inflammatory arthritis.

No description available.

Purpose: To determine whether reduced serum levels of AHSG and elevated levels of BMP-2, 4, 7 are associated with post-arthroplasty HO. Patients: Thirty arthroplasty patients were included, 15 with evidence of peri-articular HO and 15 without (NHO). Methods: Blood samples were collected from all patients ≥ 8 weeks after arthroplasty. Analytes were measured using ELISAs. Mann-Whitney U tests were performed to compare serum analyte concentrations between HO and NHO groups, and between arthroplasty patients and healthy humans. Results: There is no difference in serum concentrations of AHSG, BMP-2, 4, 7 between HO and NHO patients. Arthroplasty patients showed significantly higher BMP-2 and BMP-4 and lower AHSG serum levels compared to healthy humans (p < 0.01). Conclusion: Baseline BMP-2, 4, 7 and AHSG serum levels are not markers of acquired HO. However, elevated baseline levels of BMP- 2, 4 and reduced levels of AHSG appear to be markers of severe inflammatory arthritis.

Human platelets glycoprotein VI (GPVI) is evidenced to be a platelet receptor of major importance in the occurrence of arterial thrombosis. Thus, it can be considered to be of great interest in diagnosis and therapeutic of atheriosclerotic diseases. Antibodies are powerful molecules which can be used in both diagnostic as well as for therapeutic purposes due to their unique characteristics. Monoclonal and recombinant antibodies have antigen restricted specificity, high affinity and can be used in various assays. Moreover, the good knowledge of their structure and molecular engineering facilities now allows the antibody modulation according to desired properties.Our group has already produced several monoclonal antibodies to human GPVI by gene gun immunization against the immunoadhesin hGPVI-Fc, which differ in fine epitopespecificity, affinity and other functional properties (Lecut et al. 2003). One, 3J24, with diagnostic potential while the other, 9O12, has a therapeutic potential because it blocks the binding of GPVI to collagen. Its Fab fragment has been extensively characterized in vitro,ex vivo and in vivo for its antithrombotic properties.Here, we designed and reshaped a single-chain antibody fragment (scFv) based on 3J24variable domains for the quantification of GPVI with diagnostic potential. We were also involved in the design, production and functional evaluation of humanized anti-GPVI recombinant antibody fragments (scFvs and Fabs) with therapeutic properties.

Absorption of drug substances across the intestinal epithelium is a complex and dynamic process. Counter transport proteins are responsible for the efflux of specific drug molecules after they have been absorbed. One of the key counter transport efflux proteins, which is of importance in this study, is P–glycoprotein. The efflux pump P–glycoprotein plays a major role in altering the pharmacokinetics of a wide variety of drugs limiting their absorption and therefore also bioavailability. Many flavonoids have been shown to interact with P–glycoprotein mediated efflux in vitro studies. Numerous in vitro methods have been used to study drug absorption across the intestinal membranes, but it is often not possible to use only one in vitro model to accurately predict permeability characteristics. The purpose of this study was to determine the effect of four selected hydroxy– and methoxy– flavonoids on the in vitro transport of Rhodamine 123, a known P–gp substrate, across excised rat and pig intestinal tissue using the Sweetana–Grass diffusion apparatus. The results were further used to determine if the two different animal tissue models corresponded with regard to the flavonoids' effects on P–glycoprotein related efflux. Two control groups were included in the experimental design. In the negative control group, the transport of Rhodamine 123 was tested alone and no modulator was added. In the positive control group, the transport of Rhodamine 123 was determined in the presence of Verapamil, which is a known P–glycoprotein inhibitor. The experiments with the flavonoids Morin, Galangin, 6–Methoxyflavone and 7–Methoxyflavone were done in triplicate to determine repeatability of the results. The transport of Rhodamine 123 was evaluated in both the apical to basolateral (absorptive) and basolateral to apical (secretory) directions. The relative transport of Rhodamine 123, the apparent permeability coefficient (P app) values and flux (J) values in both directions as well as the efflux ratio (ER) and net flux (J net) were calculated. The concentration Rhodamine 123 present in the acceptor chamber was determined by means of a validated HPLC method. Statistical analysis was used to compare the results of the test groups with the control groups in order to indicate significant differences. It has been found that Morin, Galangin and 6–Methoxyflavone have a significant inhibitory effect on the Rhodamine 123 efflux (probably P–glycoprotein related) in both the rat and pig intestinal tissue models with p–values smaller than 0.05. On the other hand, 7–Methoxyflavone showed a significant effect on the efflux of Rhodamine 123 in the pig intestinal tissue model (p < 0.05) but not in the rat intestinal tissue model (p > 0.05). These flavonoids may increase the bioavailability of drugs that are substrates for P–glycoprotein and thereby cause clinically significant pharmacokinetic interactions, however, this should be confirmed with in vivo studies. On the other hand, these flavonoids may be used for drug absorption enhancement when applied under controlled circumstances. With regard to the different animal tissue models used it can be concluded that data obtained from the rat intestinal tissue model cannot be compared and extrapolated to data obtained from the pig intestinal tissue model. It is recommended that the in vitro results be correlated to in vivo findings to identify the most suitable model. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2011.

Absorption of drug substances across the intestinal epithelium is a complex and dynamic process. Counter transport proteins are responsible for the efflux of specific drug molecules after they have been absorbed. One of the key counter transport efflux proteins, which is of importance in this study, is P–glycoprotein. The efflux pump P–glycoprotein plays a major role in altering the pharmacokinetics of a wide variety of drugs limiting their absorption and therefore also bioavailability. Many flavonoids have been shown to interact with P–glycoprotein mediated efflux in vitro studies. Numerous in vitro methods have been used to study drug absorption across the intestinal membranes, but it is often not possible to use only one in vitro model to accurately predict permeability characteristics. The purpose of this study was to determine the effect of four selected hydroxy– and methoxy– flavonoids on the in vitro transport of Rhodamine 123, a known P–gp substrate, across excised rat and pig intestinal tissue using the Sweetana–Grass diffusion apparatus. The results were further used to determine if the two different animal tissue models corresponded with regard to the flavonoids' effects on P–glycoprotein related efflux. Two control groups were included in the experimental design. In the negative control group, the transport of Rhodamine 123 was tested alone and no modulator was added. In the positive control group, the transport of Rhodamine 123 was determined in the presence of Verapamil, which is a known P–glycoprotein inhibitor. The experiments with the flavonoids Morin, Galangin, 6–Methoxyflavone and 7–Methoxyflavone were done in triplicate to determine repeatability of the results. The transport of Rhodamine 123 was evaluated in both the apical to basolateral (absorptive) and basolateral to apical (secretory) directions. The relative transport of Rhodamine 123, the apparent permeability coefficient (P app) values and flux (J) values in both directions as well as the efflux ratio (ER) and net flux (J net) were calculated. The concentration Rhodamine 123 present in the acceptor chamber was determined by means of a validated HPLC method. Statistical analysis was used to compare the results of the test groups with the control groups in order to indicate significant differences. It has been found that Morin, Galangin and 6–Methoxyflavone have a significant inhibitory effect on the Rhodamine 123 efflux (probably P–glycoprotein related) in both the rat and pig intestinal tissue models with p–values smaller than 0.05. On the other hand, 7–Methoxyflavone showed a significant effect on the efflux of Rhodamine 123 in the pig intestinal tissue model (p < 0.05) but not in the rat intestinal tissue model (p > 0.05). These flavonoids may increase the bioavailability of drugs that are substrates for P–glycoprotein and thereby cause clinically significant pharmacokinetic interactions, however, this should be confirmed with in vivo studies. On the other hand, these flavonoids may be used for drug absorption enhancement when applied under controlled circumstances. With regard to the different animal tissue models used it can be concluded that data obtained from the rat intestinal tissue model cannot be compared and extrapolated to data obtained from the pig intestinal tissue model. It is recommended that the in vitro results be correlated to in vivo findings to identify the most suitable model. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2011.

Infertility affects 15 % of couples, which corresponds to 60 - 80 million worldwide. The microenvironments in which the oocyte, embryo and fetus mature are vital to the establishment and development of a healthy pregnancy. Different biological systems, such as angiogenesis, the immune system and apoptosis need to be adequately regulated for pregnancy to occur and progress normally. The overall aim of this thesis was to investigate the impact of Histidine-rich glycoprotein (HRG) and Src homology 2 domain-containing adapter protein B (SHB) on human female fertility. HRG is a plasma protein that regulates angiogenesis, the immune system, coagulation/fibrinolysis and apoptosis, by building complexes with various ligands. The impact of HRG on fertility is studied here for the first time. HRG is present in follicular fluid, the Fallopian tube, endometrium, myometrium and placenta. HRG distribution within embryo nuclei depends on developmental stage. Blastocysts express and secrete HRG. The HRG C633T single nucleotide polymorphism (SNP) appears to affect the chance of pregnancy and, correspondingly, parameters associated with pregnancy in IVF. Additionally, this HRG genotype may increase the risk in IVF of only developing embryos unfit for transfer. SHB is an adaptor protein involved in intracellular signaling complexes that regulate angiogenesis, the immune system and cell proliferation/apoptosis. Shb knockout mice have altered oocyte/follicle maturation and impaired embryogenesis. The impact of three SHB polymorphisms (rs2025439, rs13298451 and rs7873102) on human fertility is studied for the first time. The SNP prevalences did not differ between infertile and fertile women. BMI, gonadotropin dosages, the percentage of immature oocytes, the number of fertilized oocytes, the percentage of good-quality embryos and the day of embryo transfer seems to be affected by SHB genotype. In conclusion, HRG and SHB appear to influence female fertility. They are potential biomarkers that might be used for predicting pregnancy chance in infertile women. Knowledge of these genotypes may improve patient counseling and individualization of treatment.

Gene delivery for therapeutic purposes is quickly emerging as the best potential treatment option for inherited genetic diseases and cancer. Viral gene carriers have been the choice for this purpose due to their high efficiency, but harmful immunogenic and oncogenic host reactions have limited their in vivo use. Cationic polymers provide a safe alternative to viral carriers as they can be engineered to reduce immunogenic and toxic responses and serve therapeutic purposes in the body. Due to their strong positive charge, they are able to compact the negatively charged nucleotides to small nano-sized particles appropriate for cellular uptake. Additionally, they efficiently encapsulate the highly sensitive nucleotides, and protect them against degradation by the nucleases present at the physiological milieu. In this thesis work, I have used a novel approach for gene delivery by combining the critical properties of a cationic polymer (i.e., nucleotide condensing ability) with that of a fatty acid (i.e., lipid membrane compatibility). The resulting lipid modified polymer increased delivery of our gene of interest into target cells and resulted in increased siRNA delivery for cancer gene therapy. / Biomedical Sciences